Joe Lombardo
Governor

Richard Whitley, MS
Director

DEPARTMENT OF HEALTH AND HUMAN SERVICES

DIVISION OF HEALTH CARE FINANCING AND POLICY

Helping people. It's who we are and what we do.

Stacie Weeks, JD
MPH
Administrator

March 6, 2023

Inter-Tribal Council of Nevada
Serrell Smokey, ITCN President
Tribal Chairman of Washoe Tribe
919 Highway 395 South
Gardnerville, Nevada 89410

Dear Tribal Members:

In accordance with established consultation guidelines, the Division of Health Care Financing and Policy (DHCFP) is notifying Nevada tribes of the following proposed change in policy:

Revisions to Medicaid Services Manual (MSM) Chapter 1200 – Prescribed drugs are being proposed to reflect recommendations approved on January 19, 2023, by the Drug Utilization Review (DUR) Board and to add new prior authorization criteria for Physician-Administered Drugs (PADs). The proposed changes include the adoption of new prior authorization criteria for Nucala® (mepolizumab) and Dupixent® (dupilumab) for the treatment of Hypereosinophilic Syndrome (HES), and Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP), within the Respiratory and Allergy Biologics section; addition of new PAD-specific prior authorization criteria for Ocrevus® (ocrelizumab) within the Multiple Sclerosis (MS) Agents section; addition of new prior authorization criteria for penicillamine within the new Antirheumatics section; addition of new prior authorization criteria for Rayaldee® (calcifediol) within the new Vitamins section; addition of new prior authorization criteria for Relyvrio® (sodium phenylbutyrate/taurursodiol) within the new Amyotrophic Lateral Sclerosis (ALS) section; addition of new PAD-specific clinical prior authorization criteria for Prolia® (denosumab) and Xgeva® (denosumab) within the Osteoporosis Agents section; addition of new PAD-specific prior authorization criteria and quantity limits for Abraxane® (paclitaxel protein-bound particles) within the Taxane Chemotherapy Section; addition of new PAD-specific prior authorization criteria and quantity limits for Bavencio® (avelumab) and Imfinzi® (durvalumab) within the Anti-PD-1 Monoclonal Antibodies section; addition of new PAD-specific prior authorization criteria and quantity limits for Beovu® (brolucizam-dbll) within the Ophthalmic-Macular Degeneration section; addition of new PAD-specific prior authorization criteria and quantity limits for Avastin®, Myasi®, Zirabev™, Alymsys®, and Vegzelma™ (Bevacizumab) within the ANP-Human Vascular Endothelial Growth Factor Inhibitors Rec-MC Antibody; addition of new PAD-specific prior authorization criteria and quantity limits for Darzalex® (daratumumab) within the Antineoplastic section; addition of new PAD-specific prior authorization criteria and quantity limits for Darzalex Easpro® (daratumumab and hyaluronidase-fihj) within the Antineoplastic - CD38 Specific Recombinant Monoclonal Antibody Agent section; addition of PAD-specific prior authorization criteria and quantity limits for Elaprase® (idursulfase) within the Lysosomal Enzymes section; addition of new PAD-specific related prior authorization criteria and quantity limits for Eylea® (aflibercept) within the Anti-angiogenic ophthalmic agents section; addition of new PAD-specific prior authorization criteria and quantity limits for Immune Globulins (immunoglobulin) within the Immune Globulins section; addition of new PAD-specific prior authorization criteria and quantity limits for Jemperli® (dostarlimab-gxly) and Keytruda® (pembrolizumab) within the Antineoplastic-Anti-Programmed Cell Death Receptor-1 (PD-1) section; addition of new PAD-specific prior authorization criteria and quantity

limits for Kadcyla® (adotrastuzumab emtansine) within the Antineoplastic-Antibody Drug Conjugates (ADCs) section; addition of new PAD-specific prior authorization criteria and quantity limits for Aranesp® (darbepoetin alfa) within the Recombinant Human Erythropoietin's section; addition of new PAD-specific prior authorization criteria and quantity limits for Pegfilgrastim/Colony Stimulating Factors within the Colony Stimulating Factors section.

Entities Financially Affected: No entities are financially affected.

Financial Impact on Local Government: No impact on local government is known.

If you would like a consultation regarding this proposed change in policy, please contact Monica Schiffer at (775) 684-3653 who will schedule a meeting. We would appreciate a reply within 30 days from the date of this letter. If we do not hear from you within this time, we will consider this an indication that no consultation is requested.

Casey Angres

Casey Angres (Mar 6, 2023 13:17 PST)

Sincerely,
Casey Angres
Division Compliance Chief, DHCFP

cc: Antonina Capurro, DMD, Deputy Administrator, DHCFP
Sandie Ruybalid, CPM, Deputy Administrator, DHCFP
Antonio Gudino-Vargas, SSPS III, Pharmacy Unit
Kindra Berntson, SSPS II, Pharmacy Unit
Monica Schiffer, SSPS III, Medical Programs Unit, DHCFP